Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06672393
PHASE3

A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Sponsor: Hansoh BioMedical R&D Company

View on ClinicalTrials.gov

Summary

This study has been designed to confirm the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.

Official title: A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HS-10374 in Adult Subjects With Moderate To Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

375

Start Date

2024-11-04

Completion Date

2026-06-29

Last Updated

2024-11-04

Healthy Volunteers

No

Conditions

Interventions

DRUG

HS-10374 6mg tablets

Specified dose of HS-10374 tablets administered orally QD on specified days

DRUG

HS-10374-matched placebo tablets

Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days

Locations (1)

Huashan Hospital affiliated to Fudan University

Shanghai, Shanghai Municipality, China